AKT1 and thyroid gland carcinoma: In summary, the present study for the first time demonstrates robust NIS expression and radioiodine uptake in several non-thyroid cancer cells by simultaneously targeting the MAP kinase and PI3K/Akt pathways and HDAC using their inhibitors.